

## AMENDMENTS TO CLAIMS

1-7. **(Canceled)**

8. **(Currently Amended)** A method of treating muscle hyperactivity, comprising administering a purified botulinum neurotoxin that is free from a non-toxic protein of the botulinum toxin, to a patient with muscle hyperactivity.

9. **(Previously Presented)** The method of treatment according to claim 8, wherein the muscle hyperactivity is a disease that needs treatment with a fast acting remedy.

10. **(New)** The method of treatment according to claim 8, wherein the purified botulinum neurotoxin is administered in a composition that also comprises a botulinum neurotoxin-stabilizing substance other than the non-toxic protein of the botulinum toxin.

11. **(New)** The method of treatment according to claim 10, wherein the botulinum neurotoxin-stabilizing substance is human serum albumin.

12. **(New)** The method of treatment according to claim 8, wherein the botulinum neurotoxin is derived from botulinum toxin type A, B, C, D, E, or F.

13. **(New)** The method of treatment according to claim 8, wherein the muscle hyperactivity is dystonia.

14. **(New)** The method of treatment according to claim 9, wherein the administering is conducted while the dosage is adjusted until the effective dose is determined.

15. **(New)** The method of treatment according to claim 9, wherein the muscle hyperactivity is systemic muscle hyperactivity.

16. **(New)** The method of treatment according to claim 15, wherein the systemic muscle hyperactivity is generalized dystonia or systemic spasticity.